Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Israel
  4. TEL AVIV STOCK EXCHANGE
  5. Evogene Ltd.
  6. News
  7. Summary
    EVGN   IL0011050551

EVOGENE LTD.

(EVGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Evogene : NOTICE OF 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 3, 2021 ________________________ (Form 6-K)

06/23/2021 | 07:33am EDT
NOTICE OF 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS
TO BE HELD ON AUGUST 3, 2021
________________________
Evogene Ltd. Shareholders:
We cordially invite you to attend the 2021 Annual General Meeting of Shareholders, or the Meeting, of Evogene Ltd., or the Company, to be held at 3:00 p.m. (Israel time) on Tuesday, August 3, 2021, at our offices at 13 Gad Feinstein Street, Park Rehovot, Rehovot 7612002, Israel. At the meeting, the following proposals will be on the agenda:

1.
Re-election of each of (a) Ms. Sarit Firon (including her compensation as chairperson of the board, if re-elected, which compensation shall apply to future chairpersons of our Board), (b) Mr. Ziv Kop, (c) Dr. Adrian Percy, (d) Mr. Leon Y. Recanati and (e) Dr. Oded Shoseyov as a director of the Company, until the Company's next annual general meeting of shareholders and until his or her successor is duly elected and qualified.

2.
Adoption of a new compensation policy for the Company's office holders (as defined under the Israeli Companies Law, 5759-1999, or the Companies Law).

3.
Approval of an amendment to the equity component of the compensation package of each of our directors, current and future.

4.
Approval of an annual cash bonus for the Company's President and Chief Executive Officer, subject to performance matrices to be approved by the Company's compensation committee and Board on an annual basis.

5.
Approval of an increase in the salary of the Company's President and Chief Executive Officer.

6.
Adoption of a new equity incentive plan, the Evogene Ltd. 2021 Share Incentive Plan.

7.
Approval of the re-appointment of Kost Forer Gabbay & Kasierer, registered public accounting firm, a member firm of Ernst & Young Global, as the Company's independent registered public accounting firm for the year ending December 31, 2021 and until the Company's next annual general meeting of shareholders, and the authorization of the Board or the audit committee thereof to fix such accounting firm's annual compensation.
In addition to the foregoing agenda items, at the Meeting, representatives of the Company's management will be available to review and discuss the Company's financial statements for the year ended December 31, 2020.
The approval of each of the above proposals requires the affirmative vote of the holders of a majority of the voting power represented at the Meeting in person or by proxy and voting on the proposals (excluding abstentions). The approval of each of Proposals 2, 3 (in the event that Proposal 2 is not approved), 4 and 5 is also subject to satisfaction of one of the following additional voting requirements:


the majority voted in favor of the proposal must include a majority of the shares held by non-controlling shareholders who do not have a conflict of interest (referred to in the Israeli Companies Law, 5759-1999, or the Companies Law, as a 'personal interest') in the approval of the proposal that are voted at the Meeting, excluding abstentions; or

the total number of shares held by non-controlling, non-conflicted shareholders (as described in the previous bullet-point) voted against the proposal must not exceed two percent (2%) of the aggregate voting rights in the Company.
For purposes of the above special voting requirements, to the best of our knowledge, there are no shareholders who would be deemed 'controlling shareholders' of our Company under the Companies Law.
Our Board unanimously recommends that you vote in favor of each of the above proposals, which are described in the accompanying proxy statement that we are sending to our shareholders. That proxy statement and the enclosed proxy card are being furnished to the Securities and Exchange Commission, or the SEC, in a Report of Foreign Private Issuer on Form 6-K, which may be obtained for free from the SEC's website at www.sec.gov and from our website at http://www.evogene.com/investor-relations/. The proxy statement and proxy card are also available on MAGNA, the distribution site of the Israeli Securities Authority, at www.magna.isa.gov.il, and copies thereof may furthermore be obtained by contacting our Company at 13 Gad Feinstein Street, Park Rehovot, P.O.B. 4173, Ness Ziona, 7414003, Israel, Attention: Guy Kofman, Legal Advisor and Sassi Masliah, VP Legal Affairs & Company Secretary, e-mail addresses guy.kofman@evogene.com, sassi.masliah@evogene.com, telephone number (+972-8-931-1900).


Holders of record of our ordinary shares (including beneficial holders who hold their shares through a bank, broker or other nominee that is a holder of record) as of the close of business on Tuesday, June 29, 2021 are entitled to vote at the Meeting.
All shareholders are cordially invited to attend the Meeting in person. If you are unable to attend the Meeting in person, you should vote or provide voting instructions remotely in one of the below manners, depending on how you hold your ordinary shares. Detailed voting instructions will be provided both in the proxy statement and on the proxy card or voting instruction form that will be sent to you:

If you are a shareholder of record, you may vote by completing, dating and signing the enclosed form of proxy, which should be mailed, postage-free (if mailed in the United States) in the enclosed envelope to our United States transfer agent, American Stock Transfer & Trust Company. Alternatively, you may send a completed, signed proxy card directly to our Legal Advisor or VP Legal Affairs & Company Secretary at our Company's registered offices, including via email, to the address or email addresses for those individuals provided above. We reserve the right to require additional identifying information if you submit your proxy card directly to our Company in that manner. If you mail in your proxy to our transfer agent in the enclosed envelope, it must be received by 11:59 a.m., Eastern time, on Monday, August 2, 2021 for your vote to be validly included in the tally of ordinary shares voted at the Meeting. If you send in your proxy card directly to our registered office, it must be received at least four (4) hours prior to the appointed time for the Meeting on Tuesday, August 3, 2021.

If your ordinary shares are held beneficially in 'street name', that is, in a bank or brokerage account or by a trustee or nominee, on the Nasdaq Stock Market, you should complete and submit the enclosed physical voting instruction form or an online voting instruction form (at www.proxyvote.com) in order to direct your broker, trustee or nominee how to vote your shares. Your voting instructions must be received by 11:59 p.m., Eastern time, on Sunday, August 1, 2021 to be validly implemented and reflected in the tally of ordinary shares voted at the Meeting.

If you are a beneficial owner who holds ordinary shares through a member of the Tel-Aviv Stock Exchange, or TASE, you may vote your shares in person at the Meeting by presenting a certificate signed by the TASE Clearing House member through which the shares are held, which complies with the Israel Companies Regulations (Proof of Ownership for Voting in General Meetings)-2000 as proof of ownership of the shares. You may instead send that certificate, along with a duly executed proxy (in the form to be filed by us on MAGNA, the distribution site of the Israeli Securities Authority, or ISA, at www.magna.isa.gov.il), to our Legal Advisor or VP Legal Affairs & Company Secretary at our Company's registered offices, including via email, to the address or email addresses for those individuals provided above. Those items must be received by us no later than six (6) hours prior to the appointed time of the Meeting for your votes to be counted. In the alternative, you may vote your shares through the electronic voting system set up by the ISA for shareholder meetings of Israeli companies whose shares are listed on the TASE, via the MAGNA online platform. Voting your shares through that system requires that you first undergo a registration process. Your vote must be submitted in that manner no later than six (6) hours before the time fixed for the Meeting. You should receive instructions about electronic voting from the TASE member through which you hold your shares.
Even if you submit your vote remotely in one of the above-described manners, if you later decide to attend the Meeting (with proper proof that you own ordinary shares, as described in the accompanying proxy statement), you may vote in person, and in that case your proxy card, voting instructions or electronic vote (as applicable) will not be counted.

As a result of the current COVID-19 (coronavirus) pandemic, the Company desires to reduce the risk of further spreading of the virus, and to safeguard the well-being of shareholders, Board and Company representatives at the Meeting.
Consequently, the Company strongly encourages shareholders to mail in their proxy cards or voting instruction forms in lieu of attending the Meeting in person. If a shareholder who holds ordinary shares as of the record date for the Meeting (July 29, 2021) nevertheless desires to attend the Meeting, he, she or it must inform the Company in advance. Any such shareholder must contact the Company's VP Legal Affairs & Company Secretary, Sassi Masliah - email (sassi.masliah@evogene.com) or telephone (+972-8-931-1900) - on or prior to 6:00 p.m., Israel time (11 a.m. Eastern time), on Sunday, July 25, 2021. If you contact the Company via email, if you are a record shareholder, please provide the name under which your shares are held of record and proof of ownership (a copy of your share certificate or a statement showing book-entry shares). If you hold your shares in 'street name' (through a bank or broker), please attach to your email the required proof of ownership described in the enclosed proxy statement for the Meeting, namely: a 'legal proxy' from the broker, trustee or nominee that holds your shares, giving you the right to vote the shares at the Meeting, along with an account statement or other proof that shows that you owned your shares as of the record date for the Meeting. You will be required to provide similar documentation if you contact the Company's VP Legal Affairs & Company Secretary via telephone.

- ii -
Based on the number of responses that the Company receives from shareholders interested in attending the Meeting, the Company will determine whether it is possible to allow those shareholders to attend physically in person in compliance with the Israeli coronavirus regulations (which may continue to evolve from time to time prior to the Meeting date). The Company will respond to the relevant shareholders by Tuesday, July 27, 2021 in order to provide to them logistical information as to how they will be able to attend the Meeting.
In accordance with the Companies Law and regulations promulgated thereunder, any shareholder of the Company holding at least 1% of the outstanding voting rights of the Company for the Meeting may submit to the Company a proposed additional agenda item for the Meeting, to the Company's offices, 13 Gad Feinstein Street, Park Rehovot, Rehovot P.O.B 4173, Ness Ziona, 7414003, Israel, Attention: Sassi Masliah, VP Legal Affairs & Company Secretary, email: sassi.masliah@evogene.com, no later than, Wednesday, June 30, 2021. To the extent that there are any additional agenda items that the Board determines to add as a result of any such submission, the Company will publish an updated notice and proxy card with respect to the Meeting, no later than Wednesday, July 7, 2021, to be furnished to the SEC under cover of a Report of Foreign Private Issuer on Form 6-K.

The form of proxy card for the meeting is available to the public on the distribution website of the ISA at http://www.magna.isa.gov.il and on the website of the TASE at http://www.tase.co.il, and has also been furnished to the SEC as an exhibit to a Report of Foreign Private Issuer on Form 6-K, which is available on the SEC's website at http://www.sec.gov. A shareholder may also request from our Company directly to receive a copy of the proxy card (by using the contact information appearing above).

By order of the Board of Directors,

/s/ Dorit Kreiner
Ms. Dorit Kreiner
Chief Financial Officer

- iii -


Disclaimer

Evogene Ltd. published this content on 23 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 June 2021 11:32:07 UTC.


ę Publicnow 2021
All news about EVOGENE LTD.
07/20EVOGENE : Corporate Presentation
PU
07/06EVOGENE : AgPlenus Announces Positive Results for a Herbicide Resistance Trait t..
AQ
07/06EVOGENE : AgPlenus Announces Positive Results for a Herbicide Resistance Trait t..
PU
07/01Evogene Ltd. Announces Management Changes
CI
06/23EVOGENE : Announces Ms. Sarit Firon to become Evogene's Chairperson of the Board
PU
06/23EVOGENE : NOTICE OF 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AU..
PU
06/23EVOGENE : Names Sarit Firon Chairperson of its Board
MT
06/23EVOGENE : Announces Ms. Sarit Firon to become Evogene's Chairperson of the Board..
PU
06/23Evogene Ltd. Appoints Sarit Firon to Serve as Chairperson of the Board
CI
06/06EVOGENE : Corporate Presentation
PU
More news
Financials (USD)
Sales 2021 0,50 M - -
Net income 2021 -29,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 117 M 116 M -
Capi. / Sales 2021 233x
Capi. / Sales 2022 83,3x
Nbr of Employees 131
Free-Float 89,4%
Chart EVOGENE LTD.
Duration : Period :
Evogene Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOGENE LTD.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Managers and Directors
Ofer Haviv President & Chief Executive Officer
Dorit Kreiner Chief Financial Officer
Martin S. Gerstel Chairman
Mark Kapel Executive Vice President-Technology
Eyal Emmanuel Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
EVOGENE LTD.-40.73%114
JOHNSON & JOHNSON9.71%454 682
ROCHE HOLDING AG11.50%329 752
PFIZER, INC.14.37%235 663
NOVARTIS AG-0.44%221 987
ELI LILLY AND COMPANY44.27%221 420